Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celldex Therapeutics

20.66
-0.0500-0.24%
Post-market: 20.660.00000.00%16:05 EDT
Volume:598.56K
Turnover:12.48M
Market Cap:1.37B
PE:-8.43
High:21.23
Open:20.94
Low:20.64
Close:20.71
Loading ...

Canada's Northern Graphite plans to put Quebec mine on care and maintenance

Reuters
·
01 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

Celldex Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
28 Apr

BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly

Reuters
·
20 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, QXO, PDD Holdings

Reuters
·
20 Mar

BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment

Reuters
·
20 Mar

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target

MT Newswires Live
·
20 Mar

Celldex Therapeutics Initiated at Overweight by Morgan Stanley

Dow Jones
·
20 Mar

Celldex Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
04 Mar

Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
03 Mar

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

GlobeNewswire
·
03 Mar

Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Celldex announces data from Phase 2 barzolvolimab studies

TIPRANKS
·
02 Mar

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

GlobeNewswire
·
02 Mar

Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.
·
01 Mar

Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
28 Feb

Celldex Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Celldex: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

Celldex Therapeutics Q4 2024 GAAP EPS $(0.71), Inline, Sales $1.18M Beat $1.12M Estimate

Benzinga
·
28 Feb